IQVIA (NYSE:IQV) Hits New 1-Year High – Should You Buy?

IQVIA Holdings Inc. (NYSE:IQV)’s stock price reached a new 52-week high during trading on Tuesday . The company traded as high as $272.00 and last traded at $270.9470, with a volume of 425985 shares. The stock had previously closed at $265.67.

Wall Street Analysts Forecast Growth

IQV has been the topic of several recent research reports. Morgan Stanley reaffirmed an “equal weight” rating and set a $200.00 target price (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. Stifel Nicolaus increased their price target on IQVIA from $220.00 to $276.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Robert W. Baird lifted their price objective on IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft set a $240.00 target price on IQVIA in a research report on Thursday, July 9th. Finally, TD Cowen increased their target price on IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $243.62.

IQVIA Stock Up 1.7%

The firm has a 50 day simple moving average of $237.75 and a two-hundred day simple moving average of $196.87. The stock has a market capitalization of $44.46 billion, a P/E ratio of 33.55, a PEG ratio of 2.24 and a beta of 1.18. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. During the same quarter last year, the company posted $2.81 EPS. The company’s revenue for the quarter was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities research analysts expect that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

Insider Transactions at IQVIA

In other news, insider W. Richard Staub sold 5,500 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the sale, the insider directly owned 13,312 shares in the company, valued at approximately $3,097,436.16. This trade represents a 29.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Keriann Cherofsky sold 558 shares of IQVIA stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the sale, the insider directly owned 2,989 shares in the company, valued at $732,932.69. This trade represents a 15.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 15,581 shares of company stock valued at $3,796,021. Company insiders own 1.70% of the company’s stock.

Institutional Trading of IQVIA

A number of hedge funds have recently added to or reduced their stakes in IQV. BlackRock Inc. bought a new position in IQVIA during the 2nd quarter valued at $2,811,292,000. Geode Capital Management LLC grew its stake in shares of IQVIA by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock worth $982,272,000 after acquiring an additional 24,453 shares in the last quarter. Boston Partners raised its holdings in shares of IQVIA by 14.9% in the fourth quarter. Boston Partners now owns 4,087,380 shares of the medical research company’s stock valued at $923,276,000 after purchasing an additional 530,672 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of IQVIA by 16.2% during the fourth quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock valued at $856,468,000 after purchasing an additional 528,753 shares in the last quarter. Finally, Norges Bank purchased a new position in IQVIA during the fourth quarter worth about $497,445,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc is a global provider of advanced analytics, technology solutions and contract research services for the life sciences industry. The company supports pharmaceutical, biotechnology and medical device companies throughout the product life cycle, from research and clinical development through commercialization and post-market activities.

Its offerings include clinical trial management, site and patient services, real-world evidence, healthcare data, regulatory and safety services, commercial analytics, consulting, and technology platforms.